Effect of Borago officinalis extract on moderate persistent asthma

Effect of Borago officinalis extract of clinical findings and physiological parameters of moderate Asthma. A double blind placebo-controlled randomized clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201408052695N6

Enrollment

Registered

2014-12-25

Start date

2015-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

j459. asthma , unspecified

Interventions

Intervention 1: Moderate stage asthmatic subjects who were not previously treated will be evaluated for clinical findings, spirometry, asthma control test, FENO, sputum cytology, IL-4 ? IFN-? ? IL-17

Treatment - Drugs

Placebo

Moderate stage asthmatic subjects who were not previously treated will be evaluated for clinical findings, spirometry, asthma control test, FENO, sputum cytology, IL-4 ? IFN-? ? IL-17 and TLR-2 at the

Moderate stage asthmatic subjects who randomly were allocated in control group will be evaluated for clinical findings, spirometry, asthma control test, FENO, sputum cytology, IL-4 ? IFN-? ? IL-17 and

Eligibility

Sex/Gender

All

Age

15 Years to 69 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: New subjects suffering from cough and/or dyspnea; a history of intermittent course; history of airway hyper responsiveness; FEV1 between 60-79% of predicted value. Exclusion criteria: Previous treatment for asthma; active infection; bronchial disease other than asthma; cigarette smoking; sinusitis; GERD.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Asthma control test (ACT). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ACT questionnaire.;Fraction of expiratory Nitric Oxide (FENO). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: expiratory nitric oxide test with NObreath equipment.	—

Secondary

Measure	Time frame
Dyspnea. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: MMRC questionnaire.;Forced expiratory volume in one second. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: Spirometry.;Inflammatory cells of sputum. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: sputum cytology.;Interleukin -4 (IL-4). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Interleukin-17 (IL-17). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Interferon-Y (INF-Y). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Toll Like Receptor-2 (TLR-2). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Cough. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: Questionnaire.	—

Measure

Time frame

Dyspnea. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: MMRC questionnaire.;Forced expiratory volume in one second. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: Spirometry.;Inflammatory cells of sputum. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: sputum cytology.;Interleukin -4 (IL-4). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Interleukin-17 (IL-17). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Interferon-Y (INF-Y). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Toll Like Receptor-2 (TLR-2). Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: ELIZA.;Cough. Timepoint: At the beginning of the study and at the end of the 10 days treatment. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Mirsadraei

Islamic Azad University- Mashhad Branch

majidmirsadraee@mshdiau.ac.ir+98 51 3225 0044

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026